RHYTHM PHARMACEUTICALS, INC. Revenue
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Revenue of $71.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $71.25M, a 46.91% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $60.11M, a 83.81% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $57.25M, a 36.87% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $51.30M, a 54.28% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $189.76M, a 45.83% increase from fiscal 2024.
- RHYTHM PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $130.13M, a 68.06% increase from fiscal 2023.
- RHYTHM PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $77.43M, a 227.56% increase from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $23.64M, a 649.46% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $71.25M 10-Q · filed 2026-08-04 | $131.37M 10-Q · filed 2026-08-04 | $188.62M derived: sum of 3 quarters · filed 2026-08-04 | $239.92M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $60.11M 10-Q · filed 2026-05-05 | $117.36M derived: sum of 2 quarters · filed 2026-05-05 | $168.66M derived: sum of 3 quarters · filed 2026-05-05 | $217.16M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $57.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $108.55M derived: sum of 2 quarters · filed 2026-02-26 | $157.05M derived: sum of 3 quarters · filed 2026-08-04 | $189.76M 10-K · filed 2026-02-26 |
| 2025-09-30 | $51.30M 10-Q · filed 2025-11-04 | $99.80M derived: sum of 2 quarters · filed 2026-08-04 | $132.50M 10-Q · filed 2025-11-04 | $174.33M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $48.50M 10-Q · filed 2026-08-04 | $81.21M 10-Q · filed 2026-08-04 | $123.04M derived: sum of 3 quarters · filed 2026-08-04 | $156.29M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $32.70M 10-Q · filed 2026-05-05 | $74.53M derived: sum of 2 quarters · filed 2026-05-05 | $107.78M derived: sum of 3 quarters · filed 2026-05-05 | $136.86M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $41.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $75.08M derived: sum of 2 quarters · filed 2026-02-26 | $104.16M derived: sum of 3 quarters · filed 2026-02-26 | $130.13M 10-K · filed 2026-02-26 |
| 2024-09-30 | $33.25M 10-Q · filed 2025-11-04 | $62.33M derived: sum of 2 quarters · filed 2025-11-04 | $88.30M 10-Q · filed 2025-11-04 | $112.53M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $29.08M 10-Q · filed 2025-08-05 | $55.05M 10-Q · filed 2025-08-05 | $79.28M derived: sum of 3 quarters · filed 2026-02-26 | $101.78M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $25.97M 10-Q · filed 2025-05-07 | $50.20M derived: sum of 2 quarters · filed 2026-02-26 | $72.70M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $24.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $46.74M derived: sum of 2 quarters · filed 2026-02-26 | $77.43M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $22.50M 10-Q · filed 2024-11-06 | $53.19M 10-Q · filed 2024-11-06 | ||
| 2022-12-31 | $23.64M 10-K · filed 2025-02-28 | |||
| 2021-12-31 | $3.15M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |